Last update March 19, 2024
Limited compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Cinacalcet Hydrochloride in other languages or writings:
Cinacalcet Hydrochloride belongs to this group or family:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 20 - 25 vs 50 - 80 | % |
Molecular weight | 394 | daltons |
Protein Binding | 93 - 97 | % |
VD | 13.9 | l/Kg |
pKa | 10.3 | - |
Tmax | 2 - 6 | hours |
T½ | 30 - 40 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
alcimimetic that reduces plasma levels of parathyroid hormone (PTH) and secondarily calcium levels. Indicated in the treatment of secondary hyperparathyroidism in patients with chronic renal failure on dialysis, hypercalcemia due to parathyroid carcinoma or primary hyperparathyroidism not amenable to parathyroidectomy (Dillon 2011, Muñoz 2009). Oral administration once or twice daily for weeks to months.
At the time of last update, we found no published data on its excretion in breast milk.
Its pharmacokinetic data (EMA 2017), -large volume of distribution and high percentage of binding to plasma proteins-, make passage into milk of significant amounts unlikely, but its prolonged half-life, its basic character (high pKa) and the prolonged duration of treatment could facilitate this.
Although its bioavailability is very low on an empty stomach (20-25%), it increases considerably (50-80%) with meals (EMA 2017), then cinacalcet that would have been excreted in breast milk could be well absorbed by the infant.
Possible adverse reactions are frequent and serious: hypocalcemia, seizures, arrhythmias, angioedema.... (EMA 2017)
Pending further published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity. Consider paraidectomy whenever possible. (Keutgen 2012)
If administered during breastfeeding, the infant's clinical status and plasma levels of calcium and PTH should be monitored periodically.